EDMONTON, ALBERTA -- (MARKET WIRE) -- May 16, 2007 -- ViRexx Medical Corp. (‘ViRexx”)(TSX: VIR)(AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, releases the below address to shareholders in its Q1 Interim Report.
